2006年8月4日
杜邦announced it has entered a research agreement withAffinergy, Inc., a Duke University spinout, to assist in the company's research and development of a new line of bio-based products for its BioSurfaces business. Financial terms were not disclosed.
杜邦selected Affinergy because of its expertise in site-specific biological delivery technology, called Interfacial Biomaterials. This technology is complementary to the peptide technology being developed by DuPont scientists for its BioSurfaces business, which seeks to combine DuPont's biotechnology and coatings know-how to create new products.
“ Affinergy的技术是找到有可能兼容并与杜邦的尖端生物基础技术研究兼容的涂料和材料的新型方式，”杜邦生物生物材料亚博网站下载生物外观的全球业务总监Mike Saltzberg说。“这种方法与我们与专家公司合作的策略一致，以加快基于生物的材料投资组合的开发和商业化。”亚博网站下载
"Affinergy is excited to work with a respected market leader like DuPont in applying our peptide linkers in markets outside of medical devices," said Peyton Anderson, Affinergy CEO. "DuPont's compelling vision for commercializing biotechnology-based products in their markets is backed by a serious commitment."
http://www.dupont.com